Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - License Agreements - Additional Information (Details)

v3.23.3
Commitments and Contingencies - License Agreements - Additional Information (Details) - TMRC - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
May 31, 2021
May 31, 2016
Sep. 30, 2015
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Up-front license fee       $ 1.0          
Payment of up-front license fee     $ 0.5 0.5          
Payments per indication due upon the successful achievement of clinical and regulatory milestones       $ 13.0          
Payments made upon achievement of development milestone $ 1.0 $ 2.0             $ 1.0
Fees incurred under supply management agreement         $ 1.8 $ 1.8 $ 1.8 $ 1.8